The updated use of dual HER2 blockade in breast cancer therapy: a project of an institutional experience

Received: August 24, 2019; Accepted: September 20, 2019; Published: September 23, 2019 According to SEER database, more than 3 million women live with breast cancer worldwide. A recent statistical analysis evaluated the incidence and prevalence of breast cancer in Lebanese women, and revealed that it was the most prevalent cancer in Lebanon, accounting for 20% of all cancer cases, among the highest in the world. The average age-standardized incidence rate over 11 years (2005-2015) was 96.5 per 100,000, with a significantly increasing trend over time [1]. The adherence to the most recent guidelines in the treatment of breast cancer in the Lebanese population is a must, in order to obtain the best outcomes in terms of remission and survival.